Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

APLS Apellis Pharmaceuticals Inc.

未开盘 01-07 16:00:00 EST

26.49

+2.55

+10.65%

盘后26.34

-0.15-0.57%

19:23 EST

最高26.68	最低24.02	成交量344.64万
今开24.02	昨收23.94	日振幅11.11%
总市值33.52亿	流通市值20.69亿	总股本1.27亿
成交额8,952万	换手率4.41%	流通股本7,812万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":26.49,"timestamp":1767819600000,"preClose":23.94,"halted":0,"volume":3446396,"hourTrading":{"tag":"盘后","latestPrice":26.34,"preClose":26.49,"latestTime":"19:23 EST","volume":12895,"amount":341564.941,"timestamp":1767831785113},"delay":0,"floatShares":78119932,"shares":126525218,"eps":0.35814,"marketStatus":"未开盘","change":2.55,"latestTime":"01-07 16:00:00 EST","open":24.02,"high":26.68,"low":24.02,"amount":89520773.68326,"amplitude":0.111111,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.35814,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1767862800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1510203600000,"exchange":"NASDAQ","adjPreClose":23.94,"preHourTrading":{"tag":"盘前","latestPrice":24.04,"preClose":23.94,"latestTime":"09:29 EST","volume":150,"amount":3606.4602000000004,"timestamp":1767796199999},"postHourTrading":{"tag":"盘后","latestPrice":26.34,"preClose":26.49,"latestTime":"19:23 EST","volume":12895,"amount":341564.941,"timestamp":1767831785113},"volumeRatio":1.776576,"impliedVol":0.6485,"impliedVolPercentile":0.66},"requestUrl":"/m/hq/s/APLS","defaultTab":"news","newsList":[{"id":"2593362432","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.05%报25.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593362432","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593362432?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:26","pubTimestamp":1766420813,"startTime":"0","endTime":"0","summary":"北京时间2025年12月23日00时26分，Apellis Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.05%。截至发稿，该股报25.90美元/股，成交量98.0499万股，换手率0.77%，振幅6.00%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.71%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物， 通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223002653953b84f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223002653953b84f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","APLS","BK4139","LU1093756168.USD","BK4588","BK4585","BK4505"],"gpt_icon":0},{"id":"1164590450","title":"Apellis Pharmaceuticals：Syfovre五年来的安全性概况与之前报告的数据一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1164590450","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164590450?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:09","pubTimestamp":1762949354,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals：Syfovre五年来的安全性概况与之前报告的数据一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","BK4139","APLS","LU1093756325.SGD","LU1093756168.USD","BK4585"],"gpt_icon":0},{"id":"1164914277","title":"Apellis公布5年Gale数据，显示Syfovre®（Pegcetacoplan注射液）将地理性萎缩进展延迟约1.5年","url":"https://stock-news.laohu8.com/highlight/detail?id=1164914277","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164914277?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:06","pubTimestamp":1762949194,"startTime":"0","endTime":"0","summary":"Apellis公布5年Gale数据，显示Syfovre®（Pegcetacoplan注射液）将地理性萎缩进展延迟约1.5年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1093756325.SGD","APLS","LU1093756168.USD","BK4139","BK4588","BK4505"],"gpt_icon":0},{"id":"1179108448","title":"Apellis Pharmaceuticals 第三季度基本每股收益为 1.71 美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179108448","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179108448?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:25","pubTimestamp":1761823557,"startTime":"0","endTime":"0","summary":"10月30日 - Apellis Pharmaceuticals 第三季度净收入为 2.15715 亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1093756168.USD","BK4588","BK4585","BK4505","APLS","LU1093756325.SGD"],"gpt_icon":0},{"id":"2558428502","title":"Apellis Pharmaceuticals, Inc.2025财年第二财季实现净利润-42.15百万美元，同比减少11.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558428502","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558428502?lang=zh_cn&edition=full","pubTime":"2025-08-10 00:01","pubTimestamp":1754755264,"startTime":"0","endTime":"0","summary":"8月10日，Apellis Pharmaceuticals, Inc.公布财报，公告显示公司2025财年第二财季净利润为-42.15百万美元，同比减少11.92%；其中营业收入为1.78亿美元，同比减少11.00%，每股基本收益为-0.33美元。从资产负债表来看，Apellis Pharmaceuticals, Inc.总负债6.65亿美元，其中短期债务7.42百万美元，资产负债比为1.24，流动比率为3.77。机构评级：截至2025年8月10日，当前有19家机构对Apellis Pharmaceuticals, Inc.目标价做出预测，其中目标均价为37.74美元，其中最低目标价为19.00美元，最高目标价为60.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000157a47efb7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000157a47efb7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APLS"],"gpt_icon":0},{"id":"2556338925","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556338925","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556338925?lang=zh_cn&edition=full","pubTime":"2025-08-04 23:39","pubTimestamp":1754321962,"startTime":"0","endTime":"0","summary":"北京时间2025年08月04日23时39分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.08%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.07%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物， 通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804233922a474bdc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804233922a474bdc4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","APLS","LU1093756168.USD","BK4585","BK4588","BK4139","LU1093756325.SGD"],"gpt_icon":0},{"id":"2556810090","title":"Apellis Pharmaceuticals, Inc.盘中异动 下午盘快速拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556810090","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556810090?lang=zh_cn&edition=full","pubTime":"2025-08-02 01:17","pubTimestamp":1754068662,"startTime":"0","endTime":"0","summary":"北京时间2025年08月02日01时17分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.01%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物， 通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802011742972d5d7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802011742972d5d7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4588","BK4139","LU1093756168.USD","APLS","BK4505","BK4585"],"gpt_icon":0},{"id":"1105617215","title":"异动解读 | Apellis Pharmaceuticals股价盘中大涨14.16%，季度亏损低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1105617215","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105617215?lang=zh_cn&edition=full","pubTime":"2025-07-31 21:52","pubTimestamp":1753969936,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc.今日盘中大涨14.16%，引起市场广泛关注。该公司最新发布的季度财报显示，其业绩表现优于分析师预期，成为推动股价上涨的主要因素。根据公司公布的财报，截至6月30日的季度调整后每股亏损为0.33美元，明显优于分析师平均预期的0.48美元亏损。值得注意的是，尽管本季度股价上涨了9.8%，该公司股价今年迄今仍下跌了40.5%。分析师对Apellis Pharmaceuticals保持乐观态度。华尔街给予该公司12个月目标价中位数为29.00美元，较上一交易日收盘价19.00美元高出约34.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APLS"],"gpt_icon":0},{"id":"2555402554","title":"Apellis Pharmaceuticals, Inc.盘中异动 急速上涨5.01%报19.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555402554","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555402554?lang=zh_cn&edition=full","pubTime":"2025-07-31 00:34","pubTimestamp":1753893289,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日00时34分，Apellis Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.01%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.73%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物， 通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731003449972828e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731003449972828e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","BK4585","APLS","BK4139","BK4505","BK4588","LU1093756325.SGD"],"gpt_icon":0},{"id":"2551018068","title":"Apellis Pharmaceuticals, Inc.盘中异动 临近午盘股价大涨5.20%报20.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551018068","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551018068?lang=zh_cn&edition=full","pubTime":"2025-07-14 23:48","pubTimestamp":1752508110,"startTime":"0","endTime":"0","summary":"北京时间2025年07月14日23时48分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅拉升5.20%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.10%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物， 通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714234830a44a548a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714234830a44a548a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","LU1093756325.SGD","BK4588","BK4585","LU1093756168.USD","APLS","BK4139"],"gpt_icon":0},{"id":"2518428998","title":"Apellis Pharmaceuticals, Inc.2024财年实现净利润-1.98亿美元，同比增加62.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518428998","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518428998?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449653,"startTime":"0","endTime":"0","summary":"3月9日，Apellis Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-1.98亿美元，同比增加62.57%；其中营业收入为7.81亿美元，同比增加96.73%，每股基本收益为-1.60美元。从资产负债表来看，Apellis Pharmaceuticals, Inc.总负债6.57亿美元，其中短期债务6.75百万美元，资产负债比为1.35，流动比率为4.25。机构评级：截至2025年3月9日，当前有20家机构对Apellis Pharmaceuticals, Inc.目标价做出预测，其中目标均价为43.60美元，其中最低目标价为25.00美元，最高目标价为75.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000207abef97bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000207abef97bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APLS"],"gpt_icon":0},{"id":"1130319973","title":"异动解读 | 生物技术公司Apellis Pharmaceuticals股价盘中大涨5.26%,业绩数据和机构看好预期或是主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1130319973","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130319973?lang=zh_cn&edition=full","pubTime":"2025-03-05 03:46","pubTimestamp":1741117592,"startTime":"0","endTime":"0","summary":"APLS在2025年3月4日周二盘中出现大涨5.26%的行情,引发了市场广泛关注。\n\n分析人士认为,可能是该公司最新财报数据令投资者对其长期前景看好所致。财报显示,公司去年实现营收7.81亿美元,虽然净利润略为负数,但在生物技术行业中表现尚可。同时大部分机构给予该股买入或持有评级,认为其在新药研发领域具备较强实力。\n\nAPLS是一家商业化阶段的生物制药公司,专注于免疫系统中补体反应通路相关疾病的新药研发。行业分析人士认为,公司在补体领域的技术储备较为丰富,若能顺利推出有突破性的产品,长期前景值得期待。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 生物技术公司Apellis Pharmaceuticals股价盘中大涨5.26%,业绩数据和机构看好预期或是主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APLS"],"gpt_icon":0},{"id":"2517798801","title":"Apellis Pharmaceuticals, Inc.盘中异动 大幅拉升5.03%报25.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517798801","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517798801?lang=zh_cn&edition=full","pubTime":"2025-03-05 03:36","pubTimestamp":1741117017,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日03时36分，Apellis Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.03%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.05%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305033657a25f58e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305033657a25f58e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","APLS","BK4505","BK4139","BK4585","BK4588","LU1093756325.SGD"],"gpt_icon":0},{"id":"1192955750","title":"异动解读 | 投行下调目标价致使Apellis Pharmaceuticals盘中股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192955750","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192955750?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:16","pubTimestamp":1741025814,"startTime":"0","endTime":"0","summary":"生物科技公司Apellis Pharmaceuticals(APLS)今日盘中股价大幅下挫,引发市场密切关注。\n\n投行高盛(GS)下调了该公司的股票目标价,成为该股大跌的主要推手。高盛将Apellis Pharmaceuticals的目标价由之前的36美元下调至32美元,但维持中性投资评级不变。\n\n作为分析师报告下调目标价的主要原因尚未透露,但投资者担心公司增长前景或盈利能力未达预期,导致股票遭到抛售。Apellis Pharmaceuticals盘中一度下跌逾5%,市值蒸发数亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 投行下调目标价致使Apellis Pharmaceuticals盘中股价大跌5.05%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APLS"],"gpt_icon":0},{"id":"2516365458","title":"Apellis Pharmaceuticals, Inc.盘中异动 下午盘急速下挫5.09%报23.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516365458","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516365458?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:13","pubTimestamp":1741025601,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时13分，Apellis Pharmaceuticals, Inc.股票出现异动，股价快速下跌5.09%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.22%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304021322abe6743e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304021322abe6743e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4585","BK4139","BK4505","BK4588","LU1093756168.USD","APLS"],"gpt_icon":0},{"id":"2516632237","title":"高盛：维持Apellis Pharmaceuticals(APLS.US)评级，由中性调整至中性评级, 目标价由36.00美元调整至32.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516632237","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516632237?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:54","pubTimestamp":1741013661,"startTime":"0","endTime":"0","summary":"高盛：维持Apellis Pharmaceuticals(APLS.US)评级，由中性调整至中性评级, 目标价由36.00美元调整至32.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03225448494325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["APLS"],"gpt_icon":0},{"id":"1157137146","title":"异动解读 | Apellis Pharmaceuticals Inc.盘中大跌5.31%,第四季度业绩表现不佳仍未如市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1157137146","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157137146?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:48","pubTimestamp":1740754119,"startTime":"0","endTime":"0","summary":"生物制药公司Apellis Pharmaceuticals Inc. 今日盘中股价大跌5.31%,主要原因是该公司第四季度的业绩虽然超过了去年同期,但仍未达到分析师预期。\n\n财报显示,Apellis上季度每股亏损29美分,营收同比增长45.2%至2.13亿美元。虽然营收数据超过了分析师预期,但亏损程度高于分析师此前的预期每股亏损39美分。\n\n其股价走势也引发了市场担忧,本季度股价下跌了18.5%。华尔街分析师给出的12个月目标价仍为46美元,但分析师近期对其盈利预期连续两次下调,体现出对该公司未来增长前景的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APLS"],"gpt_icon":0},{"id":"2514201153","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514201153","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514201153?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:34","pubTimestamp":1740753263,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时34分，Apellis Pharmaceuticals, Inc.股票出现异动，股价急速下跌5.12%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223423abe0eb7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223423abe0eb7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4588","BK4585","LU1093756168.USD","BK4139","APLS","BK4505"],"gpt_icon":0},{"id":"1193402188","title":"异动解读 | Apellis Pharmaceuticals Inc. (APLS) 盘前大涨9.62%,2024年Q4财报超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1193402188","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193402188?lang=zh_cn&edition=full","pubTime":"2025-02-28 20:16","pubTimestamp":1740744986,"startTime":"0","endTime":"0","summary":"生物制药公司Apellis Pharmaceuticals Inc. (APLS)今日盘前交易中大涨9.62%,引发市场关注。\n公司此前公布的2024年第四季度财报数据显示,其每股亏损为0.29美元,优于分析师预期的0.37美元;季度销售额2.1253亿美元,也超过了分析师预期的1.9835亿美元。\n出色的财报业绩提振了投资者信心,令公司股价在盘前交易中大涨。市场预计Apellis Pharmaceuticals未来业绩或将持续向好,公司在生物医药领域的前景备受看好。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APLS"],"gpt_icon":0},{"id":"1181385339","title":"Apellis Pharmaceuticals 2024年第四季度GAAP每股收益$(0.29)优于预期$(0.37)，销售额$2.1253亿优于预期$1.9835亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1181385339","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181385339?lang=zh_cn&edition=full","pubTime":"2025-02-28 20:15","pubTimestamp":1740744917,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals报告的季度每股亏损为$，比分析师的共识预期$高出21.62%。这是与去年同期销售额1.4638亿美元相比增加了45.19%。以上内容来自Benzinga Earnings专栏，原文如下：Apellis Pharmaceuticals  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 21.62 percent. This is a 60.27 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $212.53 million which beat the analyst consensus estimate of $198.35 million by 7.15 percent.  This is a 45.19 percent i","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Apellis Pharmaceuticals 2024年第四季度GAAP每股收益$(0.29)优于预期$(0.37)，销售额$2.1253亿优于预期$1.9835亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":-0.0515},{"period":"1month","weight":0.0131},{"period":"3month","weight":-0.0393},{"period":"6month","weight":0.2258},{"period":"1year","weight":-0.3037},{"period":"ytd","weight":-0.047}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0089},{"period":"3month","weight":0.0278},{"period":"6month","weight":0.1054},{"period":"1year","weight":0.162},{"period":"ytd","weight":0.0145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Apellis Pharmaceuticals, Inc.于2009年9月25日根据德拉华州法律成立。该公司是一家商业阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过在补体级联中的中心蛋白C3水平上抑制补体系统（作为免疫系统的一个组成部分）来治疗具有高度未满足需求的疾病。2023年2月，美国食品药品监督管理局（FDA）批准了SYFOVRE，这是首个获批治疗继发于年龄相关性黄斑变性（GA）的地理萎缩的药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.029575},{"month":2,"riseRate":0.625,"avgChangeRate":0.032574},{"month":3,"riseRate":0.5,"avgChangeRate":0.022263},{"month":4,"riseRate":0.625,"avgChangeRate":0.039768},{"month":5,"riseRate":0.375,"avgChangeRate":-0.036849},{"month":6,"riseRate":0.75,"avgChangeRate":0.072936},{"month":7,"riseRate":0.625,"avgChangeRate":-0.050758},{"month":8,"riseRate":0.875,"avgChangeRate":0.155594},{"month":9,"riseRate":0.125,"avgChangeRate":-0.147812},{"month":10,"riseRate":0.375,"avgChangeRate":0.006953},{"month":11,"riseRate":0.625,"avgChangeRate":0.128375},{"month":12,"riseRate":0.777778,"avgChangeRate":0.130311}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}